Dxrx:
your world.
Your view.
Spot the dip before it costs you
If you're responsible for biomarker testing across a precision medicine portfolio, you need to know the moment testing changes. Across multiple biomarkers, brands, and indications, small changes can flag where your attention is needed first—before commercial impact grows.
Testing Rate Tracking helps you see testing activity across brands and indications earlier, helping you spot emerging declines, understand where attention is needed, and prioritize the actions that protect adoption. Because every week matters—and the earlier you see change, the more opportunity you have to protect momentum.
Follow positive tests to treating hcps
Precision medicine begins with a positive result—but it doesn't end there. It's not enough to know testing is happening. You need to know how testing is translating into positive patients, how patient volumes and trends are changing, who is treating those patients, and where timely scientific engagement can have the greatest impact while decisions are still forming.
Follow the path from positive test to treating HCP with Signal, giving you earlier visibility of the clinicians connected to every positive result and confidence that timely intelligence is reaching the field. That means your teams can prioritize engagement around real patient opportunity—focusing effort where it has the best chance to support treatment consideration and adoption.
Track how hcps are engaging
Once education is live, delivery alone does not tell you whether it's working. DXRX helps you see how HCPs are responding, how performance compares with benchmarks, and whether activity is reaching clinicians connected to patients eligible for biomarker testing.
Use Physician Engage data to identify where engagement is strong, where it needs support, and which audiences may need a different approach. So Precision Medicine marketers can move from reporting activity to optimizing engagement—with clearer evidence to support testing adoption.
Connect engagement to testing
Once HCPs are responding, the real test is whether engagement is changing what happens next.
DXRX brings HCP engagement and testing-rate trends into one view, helping you see where scientific education is landing, where biomarker testing rates are changing, and where further action may be needed.
That gives your teams clearer evidence of what worked—not just who engaged, but how engagement relates to the pathway you are trying to change. Proving that connection validates today’s investment and giving you the confidence to make smarter decisions tomorrow.
Spot the dip before it costs you
If you're responsible for biomarker testing across a precision medicine portfolio, you need to know the moment testing changes. Across multiple biomarkers, brands, and indications, small changes can flag where your attention is needed first—before commercial impact grows.
Testing Rate Tracking helps you see testing activity across brands and indications earlier, helping you spot emerging declines, understand where attention is needed, and prioritize the actions that protect adoption. Because every week matters—and the earlier you see change, the more opportunity you have to protect momentum.
Follow positive tests to treating hcps
Precision medicine begins with a positive result—but it doesn't end there. It's not enough to know testing is happening. You need to know how testing is translating into positive patients, how patient volumes and trends are changing, who is treating those patients, and where timely scientific engagement can have the greatest impact while decisions are still forming.
Follow the path from positive test to treating HCP with Signal, giving you earlier visibility of the clinicians connected to every positive result and confidence that timely intelligence is reaching the field. That means your teams can prioritize engagement around real patient opportunity—focusing effort where it has the best chance to support treatment consideration and adoption.
Track how hcps are engaging
Once education is live, delivery alone does not tell you whether it's working. DXRX helps you see how HCPs are responding, how performance compares with benchmarks, and whether activity is reaching clinicians connected to patients eligible for biomarker testing.
Use Physician Engage data to identify where engagement is strong, where it needs support, and which audiences may need a different approach. So Precision Medicine marketers can move from reporting activity to optimizing engagement—with clearer evidence to support testing adoption.
Connect engagement to testing
Once HCPs are responding, the real test is whether engagement is changing what happens next.
DXRX brings HCP engagement and testing-rate trends into one view, helping you see where scientific education is landing, where biomarker testing rates are changing, and where further action may be needed.
That gives your teams clearer evidence of what worked—not just who engaged, but how engagement relates to the pathway you are trying to change. Proving that connection validates today’s investment and giving you the confidence to make smarter decisions tomorrow.
Turning diagnostic insight into commercial action
Across pre-launch, launch and in-market growth, biopharma teams need to know where patients are emerging, where testing is slowing adoption, and which HCPs and labs need support.
Together, Reveal, Signal, and Engagement Solutions form DXRX, connecting diagnostic intelligence with scientific engagement to turn insight into coordinated commercial action.
Diaceutics Reveal turns near-real-time diagnostic activity from the Diaceutics Lab Network into actionable intelligence, with Signal identifying clinical events and treating HCPs. Our Engagement Solutions then activate the right mix of digital HCP engagement, peer-to-peer expert exchange, lab education and scientific engagement—and sustain momentum after launch, triggering HCP behavior change at the moments that matter most.
